Oral versus intravenous antibiotics for patients with Klebsiella pneumoniae liver abscess: study protocol for a randomized controlled trial

被引:11
作者
Molton, James [1 ,2 ]
Phillips, Rachel [3 ]
Gandhi, Mihir [3 ]
Yoong, Joanne [4 ]
Lye, David [5 ]
Tan, Thuan Tong [6 ]
Fisher, Dale [1 ,2 ]
Archuleta, Sophia [1 ,2 ]
机构
[1] Natl Univ Hlth Syst, Univ Med Cluster, Div Infect Dis, Singapore, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore
[3] Singapore Clin Res Inst, Singapore, Singapore
[4] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[5] Tan Tock Seng Hosp, Dept Infect Dis, Communicable Dis Ctr, Singapore, Singapore
[6] Singapore Gen Hosp, Dept Infect Dis, Singapore, Singapore
来源
TRIALS | 2013年 / 14卷
基金
英国医学研究理事会;
关键词
Klebsiella pneumoniae; Liver abscess; Antibiotics; Ceftriaxone; Ciprofloxacin; Outpatient; Randomized-controlled trial; Non-inferiority trial; Healthcare economics; NEEDLE ASPIRATION; CATHETER DRAINAGE; MANAGEMENT;
D O I
10.1186/1745-6215-14-364
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Klebsiella pneumoniae liver abscess is the most common etiology of liver abscess in Singapore and much of Asia, and its incidence is increasing. Current management includes prolonged intravenous antibiotic therapy, but there is limited evidence to guide oral conversion. The implicated K1/K2 capsule strain of Klebsiella pneumoniae is almost universally susceptible to ciprofloxacin, an antibiotic with high oral bioavailability. Our primary aim is to compare the efficacy of early (< one week) step-down to oral antibiotics, to continuing four weeks of intravenous antibiotics, in patients with Klebsiella liver abscess. Methods/design: The study is designed as a multi-center randomized open-label active comparator-controlled non-inferiority trial, with a non-inferiority margin of 12%. Eligible participants will be inpatients over the age of 21 with a CT or ultrasound scan suggestive of a liver abscess, and Klebsiella pneumoniae isolated from abscess fluid or blood. Randomization into intervention or active control arms will be performed with a 1:1 allocation ratio. Participants randomized to active control will receive IV ceftriaxone 2 grams daily to complete a total of four weeks of IV antibiotics. Participants randomized to intervention will be immediately converted to oral ciprofloxacin 750 mg twice daily. At Week four, all participants will undergo abdominal imaging and be assessed for clinical response (CRP < 20 mg/l, absence of fever, plus scan showing that the maximal diameter of the abscess has reduced). If criteria are met, antibiotics are stopped; if not, oral antibiotics are continued, with reassessment for clinical response fortnightly. If criteria for clinical response are met by Week 12, the primary endpoint of clinical cure is met. A cost analysis will be performed to assess the cost saving of early conversion to oral antibiotics, and a quality of life analysis will be performed to assess whether treatment with oral antibiotics is less burdensome than prolonged IV antibiotics. Discussion: Our results would help inform local and international practice guidelines regarding the optimal antibiotic management of Klebsiella liver abscess. A finding of non-inferiority may translate to the wider adoption of a more cost-effective strategy that reduces hospital length of stay and improves patient-centered outcomes and satisfaction.
引用
收藏
页数:13
相关论文
共 16 条
  • [1] CT Appearance of Pyogenic Liver Abscesses Caused by Klebsiella pneumoniae
    Alsaif, Hind S.
    Venkatesh, Sudhakar K.
    Chan, Douglas S. G.
    Archuleta, Sophia
    [J]. RADIOLOGY, 2011, 260 (01) : 129 - 138
  • [2] Antibiotic Expert Group, 2010, THER GUID ANT VERS 1
  • [3] Standardized outpatient management of Klebsiella pneumoniae liver abscesses
    Chan, Douglas S. G.
    Archuleta, Sophia
    Llorin, Ryan M.
    Lye, David C.
    Fisher, Dale
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (03) : E185 - E188
  • [4] Chen Yan-Wan, 2002, Journal of Microbiology Immunology and Infection, V35, P179
  • [5] Extended-spectrum cephalosporin compared to cefazolin for treatment of Klebsiella pneumoniae-caused liver abscess
    Cheng, HP
    Siu, LK
    Chang, FY
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2088 - 2092
  • [6] Davis J, PYOGENIC LIVER ABSCE
  • [7] Klebsiella pneumoniae genotype K1:: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess
    Fang, Chi-Tai
    Lai, Shau-Yan
    Yi, Wen-Ching
    Hsueh, Po-Ren
    Liu, Kao-Lang
    Chang, Shan-Chwen
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (03) : 284 - 293
  • [8] Lee SS-J, MOXIFLOXACIN VERSUS
  • [9] Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess
    Lee, Susan Shin-Jung
    Chen, Yao-Shen
    Tsai, Hung-Chin
    Wann, Shue-Ren
    Lin, Hsi-Hsun
    Huang, Chun-Kai
    Liu, Yung-Ching
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (05) : 642 - 650
  • [10] Liew K. V. S., 2000, SMJ Singapore Medical Journal, V41, P489